These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 8206571

  • 21. 5-HT2B-receptor antagonist LY-272015 is antihypertensive in DOCA-salt-hypertensive rats.
    Watts SW, Fink GD.
    Am J Physiol; 1999 Mar; 276(3):H944-52. PubMed ID: 10070078
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Inhibition of vasopressin action in vascular smooth muscle by the V1 antagonist OPC-21268.
    Li X, Kribben A, Wieder ED, Tsai P, Nemenoff RA, Schrier RW.
    Hypertension; 1994 Feb; 23(2):217-22. PubMed ID: 8307632
    [Abstract] [Full Text] [Related]

  • 25. Cardiovascular effects of a specific nonpeptide antagonist of substance P (NK-1) receptor in DOCA-salt hypertension.
    Kohlmann O, Ginoza M, Cezaretti ML, Zanella MT, Ribeiro AB, Tavares A, Ramos OL, Leeman SE, Gavras I, Gavras H.
    Hypertension; 1995 Dec; 26(6 Pt 2):1186-9. PubMed ID: 7498993
    [Abstract] [Full Text] [Related]

  • 26. Vasopressin and a nonpeptide antidiuretic hormone receptor antagonist (OPC-31260).
    Burrell LM, Phillips PA, Stephenson JM, Risvanis J, Johnston CI.
    Blood Press; 1994 Mar; 3(1-2):137-41. PubMed ID: 8199714
    [Abstract] [Full Text] [Related]

  • 27. Coronary vascular reactivity is improved by endothelin A receptor blockade in DOCA-salt hypertensive rats.
    Giulumian AD, Pollock DM, Clarke N, Fuchs LC.
    Am J Physiol; 1998 Jun; 274(6):R1613-8. PubMed ID: 9608015
    [Abstract] [Full Text] [Related]

  • 28. Role of vasopressin, the renin-angiotensin system and sex in Dahl salt-sensitive hypertension.
    Crofton JT, Ota M, Share L.
    J Hypertens; 1993 Oct; 11(10):1031-8. PubMed ID: 8258666
    [Abstract] [Full Text] [Related]

  • 29. Vasopressin V1a receptor antagonism does not reverse adrenocorticotrophin-induced hypertension in the rat.
    Fraser TB, Turner SW, Wen C, Li M, Burrell LM, Whitworth JA.
    Clin Exp Pharmacol Physiol; 2000 Nov; 27(11):866-70. PubMed ID: 11071300
    [Abstract] [Full Text] [Related]

  • 30. Endothelin antagonist reduces hemodynamic responses to vasopressin in DOCA-salt hypertension.
    Yu M, Gopalakrishnan V, Wilson TW, McNeill JR.
    Am J Physiol Heart Circ Physiol; 2001 Dec; 281(6):H2511-7. PubMed ID: 11709418
    [Abstract] [Full Text] [Related]

  • 31. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
    Nishimura M, Ohtsuka K, Sakamoto M, Nanbu A, Takahashi H, Yoshimura M.
    J Hypertens; 1998 Aug; 16(8):1175-85. PubMed ID: 9794722
    [Abstract] [Full Text] [Related]

  • 32. Withdrawal-induced antihypertensive effect of vasopressin in Doca-salt hypertension.
    Chiu EK, McNeill JR.
    Am J Hypertens; 1989 Jun; 2(6 Pt 1):458-61. PubMed ID: 2757802
    [Abstract] [Full Text] [Related]

  • 33. Role of endothelin and vasopressin in DOCA-salt hypertension.
    Yu M, Gopalakrishnan V, McNeill JR.
    Br J Pharmacol; 2001 Apr; 132(7):1447-54. PubMed ID: 11264238
    [Abstract] [Full Text] [Related]

  • 34. 5-Hydroxytryptamine2B receptor mediates contraction in the mesenteric artery of mineralocorticoid hypertensive rats.
    Watts SW, Gilbert L, Webb RC.
    Hypertension; 1995 Dec; 26(6 Pt 2):1056-9. PubMed ID: 7498967
    [Abstract] [Full Text] [Related]

  • 35. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats.
    Nishikimi T, Kawano Y, Saito Y, Matsuoka H.
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):275-82. PubMed ID: 8720428
    [Abstract] [Full Text] [Related]

  • 36. The role of vasopressin in essential hypertension. Plasma levels and effects of the V1 receptor antagonist OPC-21268 during different dietary sodium intakes.
    Kawano Y, Matsuoka H, Nishikimi T, Takishita S, Omae T.
    Am J Hypertens; 1997 Nov; 10(11):1240-4. PubMed ID: 9397242
    [Abstract] [Full Text] [Related]

  • 37. Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.
    Burrell LM, Phillips PA, Risvanis J, Aldred KL, Hutchins AM, Johnston CI.
    Hypertension; 1995 Nov; 26(5):828-34. PubMed ID: 7591025
    [Abstract] [Full Text] [Related]

  • 38. Treatment of brain edema with a nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats.
    Bemana I, Nagao S.
    Neurosurgery; 1999 Jan; 44(1):148-54; discussion 154-5. PubMed ID: 9894975
    [Abstract] [Full Text] [Related]

  • 39. Magnesium supplementation and deoxycorticosterone acetate--salt hypertension: effect on arterial mechanical properties and on activity of endothelin-1.
    Berthon N, Laurant P, Hayoz D, Fellmann D, Brunner HR, Berthelot A.
    Can J Physiol Pharmacol; 2002 Jun; 80(6):553-61. PubMed ID: 12117304
    [Abstract] [Full Text] [Related]

  • 40. Effects of a novel orally effective V1-receptor antagonist, OPC-21268, on AVP-induced sympathoinhibition.
    Masaki H, Imaizumi T, Harada S, Momohara M, Hirooka Y, Takeshita A.
    Am J Physiol; 1993 Jun; 264(6 Pt 2):R1089-94. PubMed ID: 8391757
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.